NeuroVax
Other names:
In development for: Relapsing remitting MS
Status: Development discontinued
Last updated: July 2010
How does it work?
NeuroVax contains a combination of three protein fragments (peptides) which appear on the surface of T-cells involved in the immune response in MS. Recent studies have suggested that treatment with NeuroVax stimulates production of certain regulatory T-cells, which in turn decrease the levels of other T-cells which attack myelin.
How is it given?
NeuroVax is injected into the muscle every four weeks.
Clinical studies
The development programme for NeuroVax was terminated when the company developing this treatment, Orchestra Therapeutics Inc, filed for bankruptcy in 2008.